Type 2 diabetes patient speaking with doctor

Patient resources

Resources created to further help you with BASAGLAR. These include videos with leading diabetes experts, published clinical studies, tips for Hispanic/Latino patients, and other information.

Give your patients the BASAGLAR Experience™

The BASAGLAR Experience offers resources designed to help patients accept, start, and stay on insulin.

Patients may be hesitant to begin basal insulin. The BASAGLAR Experience support resources may help address their initial concerns during the Insulin negotiation phase as well as help reinforce important information at home when Doing it on their own.

In patients with type 1 diabetes, BASAGLAR must be used concomitantly with short-acting insulin.1

Scroll through the steps to learn more about the BASAGLAR Experience and the resources designed to help patients accept, start, and stay on insulin.

SELECT SAFETY INFORMATION
CONTRAINDICATIONS
BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or one of its excipients.
WARNINGS AND PRECAUTIONS
BASAGLAR KwikPen® must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

Help address concerns and clear misconceptions



Living with long-acting insulin video

Video that helps dispel patient myths about insulin; available on the Beginning BASAGLAR App, online and as an in-office resource


Insulin discussion tool

Designed to help HCPs guide patients through the importance of different diabetes treatment options
Ask your BASAGLAR representative

Insulin Discussion Tool

SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.
Hypoglycemia is the most common adverse reaction associated with insulins, including BASAGLAR. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.

Help patients learn how to inject



Instructional video

Step-by-step demonstration on how to inject; available on the Beginning BASAGLAR App, online and as an in-office resource


Injection demo kit and Instructions for Use

Helps you demonstrate KwikPen® injection in your office
Ask your BASAGLAR representative

Injection Demo Kit and IFU

SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Accidental mix-ups between another insulin glargine product (100 units/mL) and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.

Help patients learn about BASAGLAR



Patient brochure

Important information to help your patients begin BASAGLAR
Ask your BASAGLAR representative

Patient Brochure


Sample kit with needles

Sample with pen needles and information about savings on prescriptions
Ask your BASAGLAR representative

Sample Kit with Needles

Help make treatment more affordable



$5 savings card for eligible patients

Find out more about eligibility requirements here

Savings Card for Eligible Patients


BASAGLAR formulary coverage

Ask your BASAGLAR representative for a local access sheet with specific coverage information for your area

BASAGLAR Formulary Coverage

SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.

Help reinforce important information at home


Beginning BASAGLAR app

An interactive experience that helps patients relax and guides them through injection using their KwikPen®

Beginning BASAGLAR App

Our mobile app gives you information you need to learn to inject—the Injection Instruction Video, Interactive Injection Guide, and more.

DOWNLOAD FOR iPHONE®/iPAD®:
  • Open the App Store, tap “Search”
  • Type “Beginning BASAGLAR,” select it, and tap “GET”
DOWNLOAD FOR ANDROID™ DEVICES:
  • Open the Google Play Store and type “Beginning BASAGLAR” in the search bar
  • Select it and tap “INSTALL”

BASAGLAR patient website

An online resource with easily accessible BASAGLAR information and insulin education

SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
All insulin products, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.

Patient savings card

For eligible commercial patients pay as little as $5 for a month’s supply of BASAGLAR
(insulin glargine injection) 100 units/mL*.

If your patients are in need of further assistance, please see below.


Each card has a unique ID number. Please do not make copies.

OR

Thank you for downloading your BASAGLAR Savings Card! Your download has begun. If there is a problem, try downloading again.

There was a problem downloading your card(s), please try again.

* Please see Savings Card for eligibility requirements and specific terms and conditions. Maximum savings up to $150/monthly prescription for eligible commercial patients. Offer is invalid for patients without commercial insurance coverage or those whose prescription claims for BASAGLAR are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DOD, VA, TRICARE/CHAMPUS, or any state patient or pharmaceutical assistance program.

Lilly Diabetes Solution Center

Lilly Diabetes Solution Center

If anyone needs help paying for BASAGLAR, they may call the Lilly Diabetes Solution Center at 1-833-808-1234, Monday through Friday from 9 AM to 8 PM, ET. A representative will have a confidential conversation and determine eligibility for solutions based on an individual’s personal circumstances.

SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Key opinion leader videos


See how Dr. Eden Miller helps her patients overcome insulin initiation challenges


Dr. Craig Wierum talks about important resources to help patients get started on BASAGLAR

SELECT SAFETY INFORMATION
ADVERSE REACTIONS
Adverse reactions commonly associated with insulin glargine products (5% or greater incidence) are: hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.

Tips for communicating with your Hispanic/Latino patients

BASAGLAR offers bilingual and culturally relevant resources that are designed to help your Hispanic/Latino patients get off to a good start. BASAGLAR also provides tools to help facilitate discussion with Hispanic/Latino patients.


HISPANIC/LATINO PATIENT RESOURCES

Visit BASAGLAR.com/espanol or contact your BASAGLAR representative for resources tailored for your Hispanic/Latino patients


HISPANIC/LATINO VIDEO RESOURCE

Follow Dr. Rosemarie Lajara through a typical day to see how she provides care for her Hispanic/Latino patients.


HISPANIC CULTURE CONNECTION

This guide offers insights and tips to help you and your staff with in-office discussions

Indications and Important Safety Information
Indication

BASAGLAR is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

LIMITATION OF USE

BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS

BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or one of its excipients.

WARNINGS AND PRECAUTIONS

BASAGLAR KwikPen® must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.

Hypoglycemia is the most common adverse reaction associated with insulins, including BASAGLAR. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.

Accidental mix-ups between another insulin glargine product (100 units/mL) and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.

All insulin products, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

ADVERSE REACTIONS

Adverse reactions commonly associated with insulin glargine products (5% or greater incidence) are: hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with BASAGLAR.

BV HCP ISI 24JUN2016

For more information, please see Full Prescribing Information, including Patient Information and Instructions for Use.

BASAGLAR and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates and are available by prescription only.

References
1. BASAGLAR [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company. 2. Lantus [Prescribing Information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2015. 3. Linnebjerg H, Lam EC, Seger ME, et al. Diabetes Care. 2015;38:2226-2233. 4. Rosenstock J, Hollander P, Bhargava A, et al. Diabetes Obes Metab. 2015;17:734-741. 5. Data on file, Lilly USA, LLC. BAS20160408A. 6. Data on file, Lilly USA, LLC. BAS20160811B. 7. Blevins TC, Dahl D, Rosenstock J, et al. Diabetes Obes Metab. 2015;17:726-733. 8. Data on file, Lilly USA, LLC. BAS20151103E. 9. Data on file, Lilly USA, LLC. BAS20160811A. 10. Gerstein HC, Yale JF, Harris SB, et al. Diabet Med. 2006;23:736-742. 11. BASAGLAR KwikPen [Instructions for Use]. Indianapolis, IN: Eli Lilly and Company.